Denali Therapeutics (DNLI) & Vericel (VCEL) Head to Head Survey

Denali Therapeutics (NASDAQ: VCEL) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Denali Therapeutics and Vericel, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics 0 1 3 0 2.75
Vericel 0 0 5 0 3.00

Denali Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 48.42%. Vericel has a consensus target price of $15.00, indicating a potential upside of 30.43%. Given Denali Therapeutics’ higher probable upside, research analysts plainly believe Denali Therapeutics is more favorable than Vericel.

Institutional and Insider Ownership

64.0% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 52.1% of Vericel shares are owned by institutional investors. 21.3% of Denali Therapeutics shares are owned by insiders. Comparatively, 4.7% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Denali Therapeutics and Vericel’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics N/A N/A -$88.18 million ($5.89) -2.75
Vericel $63.92 million 7.69 -$17.28 million ($0.50) -23.00

Vericel has higher revenue and earnings than Denali Therapeutics. Vericel is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Denali Therapeutics and Vericel’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Denali Therapeutics N/A N/A N/A
Vericel -23.35% -37.86% -21.19%

Summary

Denali Therapeutics beats Vericel on 7 of the 12 factors compared between the two stocks.

Denali Therapeutics Company Profile

Denali Therapeutics, Inc. engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply